The Lancet Refuses Senate Request on COVID-19 Origins Inquiry
The Lancet refused a U.S. Senate request for evidence on COVID-19 origins. Purdue Pharma's sentencing was delayed, while insurers moved to reduce prior-authorization paperwork.
The Lancet
CompanyRelated News
Regeneron says Phase 3 NIMBLE trial met endpoints for cemdisiran in generalized myasthenia gravis
Regeneron said the Phase 3 NIMBLE trial of cemdisiran in generalized myasthenia gravis met primary and key secondary endpoints at week 24. The company said a U.S. regulatory application has been submitted and EU filings are planned for 2026.
Phase 3 ALS Trial Launches for Pridopidine as AI Identifies Potential Drug Candidates
A phase 3 clinical trial has launched for pridopidine as a potential ALS treatment, while AI research identified 18 FDA-approved drugs that may extend survival. Separate studies found a promising three-drug combination for sporadic ALS using new cell models.